Automation replaces many manual operations in biopharmaceutical production and plays a central role in manufacturing coordination, control, and documentation. Also, batch-to-batch consistency, and continuous monitoring, can be enhanced through automation practices.
Zenith delivers automation management and process integration to its customers, supporting process and technology choices, from consultancy, systems integration to managed services.
“Zenith has grown significantly over the last number of years and now has over 700 people globally. Zenith are engaged with the top 10 life science companies and we are looking forward to continuing to work with GE Healthcare and the next-generation of manufacturing solutions. This investment by GE will further enhance our recent partnership and collaboration, and will enable an acceleration of growth for Zenith,” said Brendan O'Regan, executive chairman and founder, Zenith Technologies.
“In a complex and highly regulated industry, automation is critical for our customers, who want to establish biomanufacturing capacity quickly and at a lower cost. This is often in challenging markets, where the access to life-saving therapies is limited. With many years of experience in a wide diversity of customer applications, Zenith Technologies can strengthen our end-to-end solutions even further,” said Jan Makela, general manager, Bioprocess, GE Healthcare Life Sciences.